Analysis of metabolic extracts with 1H NMR spectroscopy proved the enzyme inhibiting capability of V-11-0711 in GBM cells as we did not detect any CHKα product - PC at 3.22 ppm – after drug exposure (Figure 7). Here, CHKA is linked to glioblastoma.